Mckesson Corporation NYSE:MCK Price, Chart, News & Insight

McKesson Barely Moves After Hours Despite Record Year as Strong Results Were Already Expected

Irving, May 7, 2026 — Shares in McKesson Corporation edged down a negligible 0.12% in after-hours trading yesterday after the healthcare distribution giant reported a fiscal fourth quarter and full year that delivered record revenue and earnings, reaffirmed its long-term growth targets, and issued fiscal 2027 guidance largely in line with what Wall Street had anticipated. The near-flat reaction is itself the story — McKesson has become such a reliable compounder that beating expectations is simply what investors expect.

Full year revenues reached $403.4 billion, up 12%, while adjusted EPS grew 18% to $39.11 — exceeding the company's own long-range targets of 13% to 16%. Fourth quarter adjusted EPS of $11.69 rose 16% year-over-year, driven by strength in oncology distribution, a lower share count, and a favorable tax rate. Free cash flow for the full year came in at $5.4 billion, and McKesson returned $5.1 billion to shareholders through buybacks and dividends.

The Oncology and Multispecialty segment was the standout, with full-year revenue surging 31% to $48.4 billion and adjusted operating profit up 53%. The US Oncology Network continued to expand, adding Cancer Care Northwest in April, and the PRISM Vision Group ophthalmology network also grew its footprint. These specialty provider businesses represent the highest-margin, highest-growth portion of McKesson's portfolio and are the primary reason the company commands a premium valuation.

Fiscal 2027 adjusted EPS guidance of $43.80 to $44.60, implying 12% to 14% growth, landed close to consensus and provided no upside surprise. The Medical-Surgical Solutions segment, which is being separated as a standalone business with Apollo Global acquiring a minority stake, continues to be a drag — adjusted operating profit there fell 5% in the quarter.

With a $7.7 billion share repurchase authorization in place and long-term EPS growth targets reaffirmed at 13% to 16%, McKesson offers exactly what its investors buy it for: predictable, compounding returns. The muted after-hours move reflects a market that got precisely what it paid for.

💬 🔗

WS Investor 05-08-26

McKesson Corporation (NYSE:MCK) declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on July 1, 2026, to shareholders of record on June 1, 2026.

💬 🔗

The Investor 04-24-26

McKesson Corporation announced that funds managed by Apollo Global Management will acquire a minority stake in its Medical-Surgical Solutions (MMS) business as part of its planned separation strategy.

Apollo will invest $1.25 billion in convertible preferred equity for an approximately 13% stake, valuing the MMS unit at around $13 billion. McKesson will retain majority ownership and operational control while preparing the business for a future initial public offering.

The transaction is positioned as a key step in McKesson’s broader plan to spin off MMS into a standalone company, with Apollo providing strategic and financial support to facilitate the transition and future growth.

The deal is subject to regulatory approvals and customary closing conditions.
Business Wire

💬 🔗

Global Finance News 04-20-26

McKesson Corporation (NYSE: MCK) will release its fourth quarter financial results after market close on Thursday, May 7, 2026.

💬 🔗

The Investor 03-07-26

McKesson Corporation announced it has completed the sale of its retail and distribution businesses in Norway to NorgesGruppen, finalizing its exit from European operations. The divestiture, first announced in August 2025, allows McKesson to concentrate capital and strategy on expanding its Oncology, Multispecialty, and Biopharma Services platforms. Additional details will be shared during the company’s fiscal third-quarter earnings call in early February.

Source: Business Wire

💬 🔗

Global Finance News 01-31-26

The Board of Directors of McKesson Corporation (NYSE: MCK) declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026.

💬 🔗

WS Investor 01-28-26

McKesson Corporation announced that it will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live earnings conference call webcast for investors at 4:30 p.m. Eastern Time on the same day.

Source: McKesson Corporation press release via Business Wire.

💬 🔗

Global Finance News 12-22-25

McKesson Corporation (NYSE: MCK) outlined its long-term growth strategy and updated financial targets at its 2025 Investor Day in Irving, Texas. The company raised its Fiscal 2026 adjusted earnings per share guidance to $38.05–$38.55, up from $37.10–$37.90, and lifted its long-term adjusted EPS growth target to 13–16% from 12–14%.

Executives highlighted strategic priorities, including strengthening North American pharmaceutical distribution, expanding oncology and biopharma services, and advancing portfolio optimization with the planned separation of its Medical-Surgical business. McKesson also introduced new segment growth targets: 5–8% for North American Pharmaceutical, 13–16% for Oncology & Multispecialty, and 10–13% for Prescription Technology Solutions.

CEO Brian Tyler said the company’s operational discipline and portfolio strength position it to drive sustainable growth and shareholder value. McKesson will release its Q2 fiscal 2026 results on November 5, 2025.

💬 🔗

European Investor 09-24-25

McKesson Corporation used its 2025 Investor Day in Irving, Texas, to outline its long-term growth strategy, highlight portfolio optimization moves, and raise financial targets.

Executives emphasized progress on strategic priorities, including strengthening North American pharmaceutical distribution, expanding oncology, multispecialty, and biopharma services, and modernizing the portfolio. The company also updated investors on the planned separation of its Medical-Surgical unit.

McKesson introduced a new organizational structure designed to sharpen its growth focus and improve transparency, while reaffirming oncology, multispecialty, and biopharma services as its primary growth pillars. Reflecting this momentum, McKesson raised its Fiscal 2026 adjusted earnings per share guidance to $38.05–$38.55, up from $37.10–$37.90.

Looking further ahead, the company lifted its long-term adjusted EPS growth target to 13–16% annually, compared to its previous 12–14% range, and set new segment growth targets: 5–8% for North American Pharmaceutical, 13–16% for Oncology & Multispecialty, and 10–13% for Prescription Technology Solutions.

CEO Brian Tyler said McKesson’s operational excellence and disciplined execution provide a strong foundation to accelerate strategic priorities and deliver sustainable value for shareholders.

💬 🔗

The Investor 09-24-25

McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

💬 🔗

WS Investor 06-27-25

NYSE:MCKFollow

NYSE:MCK